文献速递糖尿病

基于表型的2型糖尿病SGLT2抑制剂与GLP-1受体激动剂靶向治疗

Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes.
PubMed 文献 · Diabetologia · 2024-02-22

模型识别出糖化血红蛋白反应存在显著异质性,女性对GLP-1受体激动剂的反应明显优于男性,基于预测血糖反应选择治疗还与短期耐受性和长期微血管并发症风险改善相关。

要点

  • 模型识别出17.5%的患者预测SGLT2i的HbA1c获益大于GLP1-RA超过3 mmol/mol。
  • 20.3%的患者预测GLP1-RA的HbA1c获益大于SGLT2i超过3 mmol/mol。
  • 女性对GLP1-RA的血糖反应比男性高4.4 mmol/mol(95% CrI 2.2, 6.3)。

核心结论

  • 精准医学方法可促进SGLT2i与GLP1-RA治疗之间的有效个体化选择,利用常规收集的临床特征进行选择可支持在许多国家低成本部署。

主要发现

  • 模型开发识别出糖化血红蛋白反应存在显著异质性,开发队列中4787例(17.5%)预测SGLT2i相比GLP1-RA的HbA1c获益大于3 mmol/mol(>0.3%),5551例(20.3%)预测GLP1-RA相比SGLT2i的HbA1c获益大于3 mmol/mol。
  • 留出验证中校准良好,在独立苏格兰数据集的外部验证中,预测从各治疗获益的患者之间血糖结局存在明显差异。
  • 女性对GLP1-RA的反应明显更强:HARMONY-7研究中利拉鲁肽(GLP1-RA)女性比男性反应高4.4 mmol/mol(95% CrI 2.2, 6.3)(0.4% [95% CrI 0.2, 0.6])。
  • 基于预测血糖反应靶向两种治疗还与短期耐受性和长期新发微血管并发症风险的改善相关。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: A precision medicine approach in type 2 diabetes could enhance targeting specific glucose-lowering therapies to individual patients most likely to benefit. We aimed to use the recently developed Bayesian causal forest (BCF) method to develop and validate an individualised treatment selection algorithm for two major type 2 diabetes drug classes, sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1-RA). METHODS: We designed a predictive algorithm using BCF to estimate individual-level conditional average treatment effects for 12-month glycaemic outcome (HbA1c) between SGLT2i and GLP1-RA, based on routine clinical features of 46,394 people with type 2 diabetes in primary care in England (Clinical Practice Research Datalink; 27,319 for model development, 19,075 for hold-out validation), with additional external validation in 2252 people with type 2 diabetes from Scotland (SCI-Diabetes [Tayside & Fife]). Differences in glycaemic outcome with GLP1-RA by sex seen in clinical data were replicated in clinical trial data (HARMONY programme: liraglutide [n=389] and albiglutide [n=1682]). As secondary outcomes, we evaluated the impacts of targeting therapy based on glycaemic response on weight change, tolerability and longer-term risk of new-onset microvascular complications, macrovascular complications and adverse kidney events. RESULTS: Model development identified marked heterogeneity in glycaemic response, with 4787 (17.5%) of the development cohort having a predicted HbA1c benefit >3 mmol/mol (>0.3%) with SGLT2i over GLP1-RA and 5551 (20.3%) having a predicted HbA1c benefit >3 mmol/mol with GLP1-RA over SGLT2i. Calibration was good in hold-back validation, and external validation in an independent Scottish dataset identified clear differences in glycaemic outcomes between those predicted to benefit from each therapy. Sex, with women markedly more responsive to GLP1-RA, was identified as a major treatment effect modifier in both the UK observational datasets and in clinical trial data: HARMONY-7 liraglutide (GLP1-RA): 4.4 mmol/mol (95% credible interval [95% CrI] 2.2, 6.3) (0.4% [95% CrI 0.2, 0.6]) greater response in women than men. Targeting the two therapies based on predicted glycaemic response was also associated with improvements in short-term tolerability and long-term risk of new-onset microvascular complications. CONCLUSIONS/INTERPRETATION: Precision medicine approaches can facilitate effective individualised treatment choice between SGLT2i and GLP1-RA therapies, and the use of routinely collected clinical features for treatment selection could support low-cost deployment in many countries.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Cardoso P, Young KG, Nair ATN, et al. Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Diabetologia. 2024. PMID: 38388753. doi:10.1007/s00125-024-06099-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。